近年來美國專利法中最大修正的美國發明法(American Invents Act)已於2012年施行。其中新法所創設的專利審理暨訴願委員會(Patent Trial and Appeal Board,PTAB)與其轄下的複審制度:多方複審程序(Inter Partes Review,IPR)、領證後複審程序(Post Grant Review,PGR)和涵蓋商業方法專利複審程序(Covered Business Method Review,CBM)尤其受到關注。 本文聚焦探討IPR、CBM、PGR等程序的特殊之處,透過歷年累積的案件數據呈現PTAB於專利有效性爭訟時的重要地位,包括PTAB對於處理受挑戰請求項之情形以及上訴審聯邦巡上訴法院(Court of Appeals for the Federal Circuit,CAFC)審理見解之趨勢。並針對專利有效性爭訟中常作為重要爭點之關鍵:專利適格性、新穎性、非顯而易知性、請求項範圍建構、聲請修正請求項等,各以新近經過PTAB和CAFC審理之案件進行分析,藉以掌握美國專利有效性訴訟的見解趨勢,作為我國企業於爭訟時可運用之策略與參考。
The American Invents Act was passed by U.S. Congress and was signed into law on September 16, 2011. The law represents the most significant change to the U.S. patent system since 192, and closely resembles previously proposed legislation in the Senate in its previous session. The Patent Trial and Appeal Board (PTAB) was formed as one part of the American Invents Act, handling contested cases such as Inter Partes Review (IPR), Post Grant Review (PGR) and Transitional Program for Covered Bussiness Method Patents (CBM). This Study is focusing on the status and importance of IPR, PGR and CBM. By examining the statistics of number of the cases over the years, discussing the reason to value this procedure in finding the validity of patents in patent trials. The scope including presenting the condition of cases instituted in PTAB and the cases appealed to Court of Appeals for the Federal Ciruit (CAFC). Furthermore, this study lists 5 key issues in patent validity trials to observe the opoinon from the court, including patent eligibility, novelty, non-obviousness, claim construction and motion to amend. Cases were from PTAB and CAFC between 2015 and 2016. This may offer the companies in Taiwan to have better strategis to apply during U.S. patent litigation.